Page last updated: 2024-08-18

thiophenes and Atrial Fibrillation

thiophenes has been researched along with Atrial Fibrillation in 382 studies

Research

Studies (382)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (1.31)	29.6817
2010's	375 (98.17)	24.3611
2020's	2 (0.52)	2.80

Authors

Authors	Studies
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Carnicelli, AP; Fox, KAA; Halperin, JL; Hankey, GJ; Hellkamp, AS; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE	1
Ding, HY; Jiao, Z; Liu, XQ; Ma, CL; Yan, MM; Zhang, YF; Zhong, MK	1
Yavelov, IS	1
Hu, Y; Huang, S; Tang, L	1
Barrios, V; Escobar, C	1
Ageno, W; Ferrari, A; Filippi, A; Imberti, D; Palareti, G; Pengo, V; Rubboli, A; Toni, D	1
Akwaa, F; Spyropoulos, AC	1
Galanis, T; Merli, GJ	1
Berman, JP; Halperin, JL	1
Lenchus, JD	1
Apostolakis, S; Kasmeridis, C; Lip, GY	1
Chang, CJ; Chen, SA; Chen, YC; Chen, YJ; Huang, JH; Lin, YK	1
Hernández, M; Suárez, C	1
Masjuan, J	1
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR	1
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Pan, G; Patel, MR; Piccini, JP; Singer, DE	1
Armstrong, EP; Harrington, AR; Malone, DC; Nolan, PE	1
Stiefelhagen, P	3
Jeffery, SM; Ogbonna, KC	1
Badimón, JJ; Briongos Figuero, S; García Santos-Gallego, C	1
Hughes, DA; Pink, J; Pirmohamed, M	1
Harris, K; Mant, J	1
Atarashi, H	1
Darius, H; Sommer, S	1
Ahmad, Y; Lip, GY	2
Gallego, P; Lip, GY; Roldan, V	1
Carter, NJ; Plosker, GL	1
Berkowitz, SD; Burton, P; Cook-Bruns, N; DiBattiste, PM; Haskell, L; Jalota, S; Kubitza, D; Lensing, AW; Misselwitz, F; Moore, KT; Nadel, A; Nessel, CC; Oppenheimer, L; Pan, G; Perzborn, E; Peters, G; Sarich, TC; Sun, X; Weber, J; Westermeier, T	1
Aisenberg, J; Desai, J; Kolb, JM; Weitz, JI	1
Bauer, KA	1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Mahaffey, KW; Nessel, CC; Patel, MR; Singer, DE; van Diepen, S	1
Aisenberg, J; Desai, J; Granger, CB; Weitz, JI	1
Klein, HH	1
Toth, PP	1
Apostolakis, S; Lip, GY; Shantsila, E	1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hannan, KL; Hellkamp, AS; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Schwabe, K; Singer, DE	1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; White, HD; Wojdyla, D	1
Gong, IY; Kim, RB	1
Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA	1
Boos, CJ; Camm, AJ; Nam, M	1
Finsterer, J; Stöllberger, C	4
Diener, HC	1
Lopes, RD; Newby, LK; Truffa, AA	1
Lee, R; Lee, T	1
Bhimani, AA; Hong, M	1
Opolonskaia, NA; Tseluĭko, VI; Vashakidze, ZS	1
Kamal, AK; Kamran, SH; Muzammil, SM	1
Chana, F; Llau, JV; Marco, P; Zamorano, JL	1
Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D	2
Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M	1
Aguilar, MI; Freeman, WD; Kuo, RS	1
Delgado-Fernández, M	1
Hori, M; Kajikawa, M	1
Dalen, JE	1
Fanikos, J	1
Li, C; Li, T; Mao, L; Yuan, K	1
Wanat, MA	1
Avorn, J	1
Barry, M	1
Lip, GY; Potpara, TS	1
Diener, HC; Easton, JD; Hankey, GJ; Hart, RG	1
Barco, S; Cheung, YW; Coppens, M; Eikelboom, JW	1
Kansal, AR; Pokora, T; Sorensen, SV; Zheng, Y	1
Goto, S; Hori, M; Iekushi, K; Izumi, T; Kajikawa, M; Kato, M; Koretsune, Y; Matsumoto, M; Momomura, S; Tajiri, M; Tanahashi, N; Uchiyama, S; Ueda, H; Yamanaka, S	3
Apostolakis, S; Banerjee, A; Lane, DA	1
Becker, RC; Breithardt, G; Califf, RM; Chang, Y; Fox, KA; Go, AS; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR	2
Asukai, Y; De Ruyck, M; Evers, T; Faes, P; Goethals, M; Kleintjens, J; Li, X; Rietzschel, ER; Saka, Ö; Simoens, S; Thijs, V; Vansieleghem, S	1
He, B; Kun, L; Liu, X; Wu, B	1
Azuma, S; Lum, CJ	1
Hughes, DA; Lane, S; Pink, J; Pirmohamed, M	1
Gunalingam, B; Markus, R; Spina, R; Subbiah, R	1
Ando, M; Hirayama, H; Kihara, Y; Nakano, Y; Sairaku, A; Yoshida, Y	1
Atar, D; Ghanima, W; Sandset, PM	1
Kornej, J; Lip, GY; Potpara, T	1
Anisimova, AV; Borisov, SN; Gendlin, GE	1
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; White, HD	1
Diogène, E; Troncoso, A	1
Liberato, NL; Marchetti, M; Quaglini, S; Rognoni, C	1
Nagatsuka, K; Okata, T; Takasugi, J; Toyoda, K; Yamagami, H	1
Avorn, J; Brennan, TA; Canestaro, WJ; Choudhry, NK; Ito, K; Matlin, OS; Patrick, AR; Shrank, WH	1
Wood, P	1
Germain, G; Laliberté, F; Lefebvre, P; Nelson, WW; Olson, WH; Pilon, D; Raut, MK; Schein, JR	3
Gulseth, M; Hellwig, T	1
Baruch, L; Sherman, O	1
Manning, JA	1
Giugliano, RP; Murphy, SA	1
Kitazono, T	1
Uchiyama, S	1
Kreutz, R	1
Laffan, M; Shapiro, S	1
Breithardt, G; Califf, RM; Fox, KA; Halperin, J; Hankey, GJ; Hellkamp, AS; Jones, WS; Mahaffey, KW; Patel, MR; Piccini, JP; Singer, DE	1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Sherwood, MW; Singer, DE; White, HD; Wojdyla, DM	1
Baker, R; Herrmann, R; Muhammad, S; Phillips, M; Thom, J; Wood, A	1
Barillari, G; Cheng, JW	1
Adcock, DM; Deal, AM; Francart, SJ; Friedman, KD; Gosselin, R; Hawes, EM; Jeanneret, C; Moll, S	1
Atkins, D; Baheiry, S; Barrett, CD; Bommana, S; Burkhardt, JD; Chalhoub, F; Di Biase, L; Gangireddy, S; Lakkireddy, D; Mansour, MC; Natale, A; Reddy, V; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Swarup, V; Vallakati, A; Verma, A	1
Diener, HC; Weber, R	1
Aizawa, T; Kano, H; Kato, Y; Kirigaya, H; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Takai, H; Uejima, T; Yajima, J; Yamashita, T	1
Bajorek, B; Wang, Y	1
Hanon, O	1
Darvish-Kazem, S; Douketis, JD; Liew, A	1
Roberts, A	1
Bollmann, A; Breithardt, OA; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P	1
Altena, R; de Wit, H; Folkeringa, R; Hoogendoorn, M; van Roon, E	1
Giugliano, RP; Gonzalez-Quesada, CJ	1
Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H	1
Gnall, EM; Ice, DS; Kowey, PR; Shapiro, TA	1
Albenque, JP; Boveda, S; Combes, N; Combes, S; Hireche, H; Jourda, F; Marijon, E; Morais, J; Providência, R	1
Angiolillo, DJ; Capodanno, D	1
Becker, RC; Califf, RM; Douketis, JD; Fox, KA; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Sherwood, MW; Singer, DE; Spyropoulos, AC	1
Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Paikin, JS	1
Crowther, M; Pasierski, T; Undas, A; Windyga, J	1
Groh, C; Passman, R; Yadlapati, A	1
Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F	3
Gonzva, J; Lignac, D; Patricelli, R	1
Iavelov, IS	1
Badhwar, N; Gerstenfeld, EP; Lee, BK; Lee, RJ; Marcus, GM; Olgin, J; Scheinman, M; Stepanyan, G; Tseng, ZH; Vedantham, V	1
Bode, C; Haas, S; Norrving, B; Turpie, AG	1
Cloutier, M; Coleman, CI; Damaraju, CV; Laliberté, F; Lefebvre, P; Nelson, WW; Olson, WH; Pilon, D; Schein, JR	1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Garg, J; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE	1
Giugliano, RP; Reddy, P	1
Becker, RC; Califf, RM; Fox, KA; Girgis, IG; Halperin, JL; Mahaffey, KW; Moore, KT; Nessel, CC; Patel, MR; Peters, GR	1
Bolbrinker, J; Douros, A; Ebinger, M; Kreutz, R; Schlemm, L	1
Thachil, J	1
Hagen, G; Klemp, M; Wisløff, T	1
Piccini, JP; Steinberg, BA	1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR	1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Harrell, FE; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE	1
Camm, AJ; Cappato, R; Ezekowitz, MD; Hemmrich, M; Hohnloser, SH; Kirchhof, P; Klein, AL; Lanius, V; Le Heuzey, JY; Ma, CS; Meng, IL; Scanavacca, MI; Talajic, M; van Eickels, M; Vardas, PE; Wildgoose, P	1
Bookhart, B; Huynh, L; Lefebvre, P; Mody, SH; Tran, KN; Zhuo, DY	1
Davidson, N; Galloway, SW; Lai, A; Thachil, J	1
Barake, W; Baranchuk, A; Pinter, A	1
Brieger, D	1
Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T	1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Passman, R; Patel, MR; Piccini, JP; Singer, DE; Steinberg, BA	1
Foley, J; Kirchhof, P; Lip, GY	1
Avorn, J; Brennan, TA; Brill, G; Choudhry, NK; Desai, NR; Krumme, AA; Matlin, OS; Pezalla, EJ; Schneeweiss, S; Shrank, WH; Spettell, CM	1
Hürlimann, D; Noll, G; Noll, S	1
Evans, RS; Fontaine, GV; Lloyd, JF; Mathews, KD; Stevens, SM; Woller, SC	1
Corelli, K; Ezekowitz, MD; Ghosh, P; Spahr, J	1
Freedman, JE; Gersh, BJ	1
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Wojdyla, DM	1
Coleman, CI; Damaraju, CV; Nelson, WW; Schein, JR; Smith, DM; Song, X; Thomson, E	1
Du, S; Harenberg, J; Krämer, R; Krämer, S; Lip, GY; Schulze, A; Wehling, M; Weiss, C; Zolfaghari, S	1
Hess, T; Konturek, P	1
Baker, WL; Chamberlin, KW	1
Curnow, J; Joseph, J; McLintock, C; McRae, S; Nandurkar, H; Tran, H; Wood, P; Young, L	1
Dan, GA; Kaski, JC; Martínez-Rubio, A	1
Stępińska, J; Załęska-Kocięcka, M	1
Ammar, S; Buiatti, A; Deisenhofer, I; Dillier, R; Hessling, G; Hofmann, M; Kaess, B; Kathan, S; Kolb, C; Lennerz, C; Pavaci, H; Reents, T; Semmler, V	1
Chatelain, C; Devalet, B; Dogné, JM; Douxfils, J; Larock, AS; Mullier, F; Sennesael, AL; Spinewine, A	1
Aryal, MR; Bhandari, Y; Donato, A; Jalota, L; Karmacharya, P; Mainali, NR; Pandit, A; Pathak, R; Pradhan, R; Ukaigwe, A	1
Cappato, R; Davies, DW; Fields, LE; Hess, S; Hohnloser, SH; Ma, C; Marchlinski, FE; Naccarelli, GV; Natale, A; Wilber, DJ; Xiang, J	1
Fukamizu, S; Hiraoka, M; Kitamura, T; Sakurada, H	1
Berthold, C; Boecher-Schwarz, H; Dooms, G; Gunness, VR; Hana, A; Hertel, F; Koy, J; Matgé, G; Standhardt, H	1
Askonen, K; Halinen, M; Huikuri, H; Koistinen, J; Parikka, H; Puurunen, M; Raatikainen, P; Virtanen, V	1
Gerona, RR; Lo, JC	1
Brar, N; Shivamurthy, P; Therrien, ML	1
Baba, Y; Hagii, J; Hitomi, H; Iwata, M; Kamada, T; Matsumoto, S; Metoki, N; Okumura, K; Osanai, T; Saito, S; Sasaki, S; Seino, S; Shiroto, H; Takahashi, K; Tomita, H; Uchizawa, T; Yasujima, M	1
Amarenco, P; Camm, AJ; Haas, S; Hess, S; Kirchhof, P; Turpie, AG; van Eickels, M	1
Barucci, R; Fattirolli, F; Fracchia, S; Mannarino, G; Orso, F; Pratesi, A	1
Mitchell, AR; Page, PL; Thomas, R	1
Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P	1
Aryal, MR; Badal, M; Chaudhary, A; Donato, AA; Mege, J	1
Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA	1
Bonati, LH; Engelter, ST; Gensicke, H; Lyrer, P; Peters, N; Seiffge, DJ; Traenka, C; Tsakiris, DA	1
Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N	1
Guo, X; Li, L; Tang, B; Xu, G; Zhang, Y; Zhou, X	1
Bang, OY; Chung, CS; Kim, GM; Kim, JS; Kim, SJ; Lee, KH; Lee, MJ; Park, YK; Ryoo, S; Yoon, CH	1
Baumgartner, H; Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR	1
Brueckmann, M; Clemens, A; Konstantinides, S; Lip, GY; Noack, H; Strack, A	1
Rudakova, AV; Tatarskiĭ, BA	1
Dobesh, PP; Trujillo, T	1
Camm, AJ; Cappato, R; Ezekowitz, MD; Hemmrich, M; Hohnloser, SH; Kirchhof, P; Klein, AL; Lanius, V; Le Heuzey, JY; Ma, CS; Meng, IL; Scanavacca, M; Talajic, M; van Eickels, M; Vardas, PE; Wildgoose, P	1
Lane, DA; Lip, GY; Senoo, K	1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Steinberg, BA	1
Lim, GB	1
Fosbøl, EL; Gislason, GH; Hansen, ML; Køber, L; Lamberts, M; Mikkelsen, AP; Olesen, JB; Sørensen, R; Torp-Pedersen, C; Weeke, P	1
Giugliano, RP; Plitt, A	1
Madhusudhana, S; Qasem, A; Strasser, KM	1
Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S	1
Kovács, T	1
Ko, Y; Kong, MC; Lee, LH; Ng, HJ; Wang, Y; Xie, F	1
de Boer, A; Hasrat, F; Maitland-van der Zee, AH; Redekop, WK; Verhoef, TI	1
Ezekowitz, MD; Kent, AP	1
Hohnloser, SH; Lopes, RD	1
Berghold, A; Kemperdick, B; Mergenthal, K; Petersen, JJ; Rauck, S; Roehl, I; Schulz-Rothe, S; Siebenhofer, A; Ulrich, LR	1
Choi, YJ; Hong, KS; Kwon, SU	1
Mima, Y; Nagata, S; Okada, Y; Sangatsuda, Y; Wakugawa, Y; Yasaka, M	1
Baber, U; Mastoris, I; Mehran, R	1
Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R	1
Bell, AD; Douketis, J; Eikelboom, J; Liew, A	2
Rondina, M	1
da Silva, RM	1
Greco, C	1
Cairns, JA; Weitz, JI	1
Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD	1
Basaran, NF; Basaran, O; Biteker, M; Cekic, EG	1
Dogné, JM; Douxfils, J; Larock, AS; Mullier, F; Spinewine, A	1
Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L	1
Dublanchet, N; Dutheil, F; Lebreton, A; Milhaud, G; Moustafa, F; Schmidt, J	1
Forslund, T; Hjemdahl, P; Holmström, M; Johnsson, H; von Euler, M; Wettermark, B	1
Arepally, GM; Ortel, TL	1
Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB	1
Garg, P; Ripley, DP	1
Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH	1
Becker, RC; Krishnamoorthy, A; Lopes, RD; Sherwood, MW	1
Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; Washam, JB	1
Fukae, S; Izumida, S; Kawano, H; Kohno, Y; Koide, Y; Maemura, K; Takeno, M; Tsuneto, A	1
Hogg, K; Weitz, JI; Yeh, CH	1
Bailleul, E; Borrey, D; Caluwé, R; De Bacquer, D; De Vriese, AS; Emmerechts, J; Van Vlem, B; Vandecasteele, SJ	1
Cappato, R; Cohen, A; Hammerstingl, C; Kirsch, B; Lip, GY; Marin, F; Meng, IL; Morandi, E; van Eickels, M	1
Bode, C; Cohen, M; Fox, K; Gibson, CM; Halperin, J; Husted, S; Lip, GY; Mehran, R; Peterson, E; van Eickels, M; Verheugt, F; Wildgoose, P	1
Hashi, S; Penge, J; Simister, R	1
Lane, DA; Wood, K	1
Abraham, NS; Alexander, GC; Crown, W; Haas, LR; Heien, H; Shah, ND; Singh, S	1
Rose, A; Vaughan Sarrazin, MS	1
Alexander, GC; Chang, HY; Singh, S; Tang, W; Zhou, M	1
Arentz, T; Jadidi, A; Lehrmann, H; Park, CI; Pruvot, E; Weber, R; Zimmermann, M	1
Phillips, R	1
Hilpert, U	1
Lythgoe, M	1
Ay, C; Belik, S; Griesmacher, A; Königsbrügge, O; Pabinger, I; Quehenberger, P; Seger, C; Weigel, G	1
Lewis, LS	1
Botto, GL; Colonna, P; Troccoli, R	1
Bode, C; Kelm, M; Zeus, T	1
Koretz, RL	1
Fox, KA; Hellkamp, AS; Patel, MR	2
Lasek-Bal, A; Piekarski, M; Puz, P; Urbanek, T	1
Powell, JR	1
Spyropoulos, AC	1
Boyle, AJ; Yong, CM	1
Eikelboom, J; O'Donnell, M; Sobieraj-Teague, M	1
Khalabuda, M; McBride, BF; Morell, J; Sullivan, B	1
Lopes, RD; Mahaffey, KW; Piccini, JP	1
Alban, S; Völler, H; Westermann, D	1
Baumhäkel, M; Böhm, M; Schirmer, SH	1
Weitz, JI	1
Mitka, M	2
Ahrens, I; Lip, GY; Peter, K	1
Eikelboom, JW; Eriksson, BI; Quinlan, DJ	1
Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD	1
Smetana, GW; Srour, JF	1
Ageno, W; Romualdi, E	1
Samama, CM	1
Braunwald, E; Steffel, J	1
Huisman, MV; Kooiman, J; van de Peppel, WR; van der Meer, FJ	1
Ajzenberg, N; Dumont, B; Faille, D	1
Gawaz, M; Geisler, T	1
del Zoppo, GJ; Eliasziw, M	1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Garg, J; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Pan, G; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE	1
Asmis, LM	1
Büller, HR; Eerenberg, ES; Kamphuisen, PW; Sijpkens, MK; van Es, J	1
Mega, JL	1
Becker, RC; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Wojdyla, D	1
Di Pasquale, G; Riva, L	1
Agnelli, G; Decousus, H; Lensing, AW; Misselwitz, F; Mueck, W; Prandoni, P	1
Bode, C; Diener, HC; Kaeufer, T	1
Emerson, SS; Fleming, TR	1
Heidinger, K; Kemkes-Matthes, B	1
Bode, C; Moser, M	1
Niessner, A	1
Rose, A	1
Parra, D; Rosenstein, R	1
Pearson, S; Richards, AM; Troughton, R	1
Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C	1
Abu-Fadel, MS; Dib, C; Golwala, H; Tafur, A	1
Nagao, T	1
Biller, J; Flaster, M; Morales-Vidal, S; Schneck, MJ	1
Parma, Z; Syzdół, M; Tendera, M	1
Goldhaber, SZ	1
Soff, GA	1
Lip, GY; Riva, N	1
Khemasuwan, D; Suramaethakul, N	1
Lip, GY; Shantsila, A	1
Gorelick, PB	1
Becker, RC; Breithardt, G; Califf, RM; Carolei, A; Diener, HC; Donnan, GA; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Mas, JL; Massaro, A; Nessel, CC; Norrving, B; Paolini, JF; Patel, MR; Roine, RO; Singer, DE; Stevens, SR; Wong, L	1
Palareti, G; Tripodi, A	1
Samama, MM	1
Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A	1
Haas, S; Schellong, SM; Spannagl, M	1
Bommer, WJ	1
Augoustides, JG	1
Halperin, JL; Varughese, CJ	1
Lewalter, T	1
Anglade, MW; Coleman, CI; Kluger, J; Lee, S; Pham, D; Pisacane, R	1
Goto, S; Hori, M; Iwamoto, K; Izumi, T; Kajikawa, M; Kato, M; Koretsune, Y; Matsumoto, M; Momomura, S; Tajiri, M; Tanahashi, N; Uchiyama, S; Ueda, H	3
Ismael, AG; Ribowsky, JH	1
Licina, MM; Lip, GY; Polovina, MM; Potpara, TS; Prostran, MS; Stojanovic, RM	1
Ansell, J; Mantha, S	1
Ball, DG; Day, AG; Gibbens, SL; LaHaye, SA; Olesen, JB; Skanes, AC	1
Shafir, V; Spinler, SA	1
Agnifili, M; Bedogni, F; Brambilla, N; De Marco, F; Lanotte, S; Latib, A; Latini, RA; Laudisa, ML; Mattioli, R; Oreglia, J; Pizzocri, S; Testa, L	1
Larsen, TB; Rasmussen, LH; Skjøth, F	1
Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S	1
Pollack, CV	1
Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY	1
Fareed, J; Kalodiki, E; Lewis, B	1
Diener, HC; Harenberg, J; Lip, GY; Marder, VJ; Marx, S; Wehling, M; Weiss, C	1
Hashizume, K; Kajikawa, M; Kaneko, M; Mueck, W; Paolini, JF; Tajiri, M; Tanigawa, T; Ueda, H	1
Capucci, A; Prisco, D	1
Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A	1
Mangiafico, M; Mangiafico, RA	1
Harenberg, J; Marx, S; Wehling, M	1
Zhang, S	1
Yasaka, M	1
Destephan, C; Dhruvakumar, S; Gerula, C; Kaluski, E; Maher, J; Mazza, V; Patel, RJ; Waller, AH	1
Ahrens, I; Bode, C	1
Jin, M; Kamrul, R; Kosar, L; Schuster, B	1
Cannon, CP; Kohli, P	1
Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV	1
Lyrer, P; Nedeltchev, K; Seiffge, D	1
Kopecky, S	1
Giorgi, MA; Miguel, LS	1
Brouwers, PJ; Kappelle, LJ; Koudstaal, PJ; Roos, YB; van Dijk, EJ	1
Haas, S; Kreutz, R; Llau, J; Norrving, B; Turpie, AG	1
Rajappan, K	1
Esmon, CT	1
Le Heuzey, JY	1
Eikelboom, JW; Manolakos, JJ; Paikin, JS	1
Becker, RC; Chan, MY; Cyr, D; Kajikawa, M; Lin, M; Lucas, J; Moseley, A; Ortel, TL; Thompson, JW; Ueda, H	1
Gonzalez, MD; Naccarelli, GV	1
Sanaei, O	1
Koziński, M; Kubica, A; Kubica, J; Navarese, EP; Obońska, K	1
Aalbers, J	1
Blanco-Molina, A	1
Lipták, J	1
Graungaard, T; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F	1
Lazo-Langner, A; Sun, D	1
Dabitz, R; Ochs, G	1
Boehlen, F; de Moerloose, P	1
Martin, EN; Money, SR; Shamoun, FE	1
Coccheri, S; Orlando, D	1
Li, HF; Zhao, RL	1
Medvegy, M; Simonyi, G	1
Deitelzweig, SB	1
Camm, AJ; Savelieva, I	1
Greenspon, AJ	1
Ganetsky, V; Spinler, SA; Thomas, TF	1
Hashizume, K; Kajikawa, M; Kaneko, M; Mueck, W; Tajiri, M; Tanigawa, T	1
Shiga, T	1
Christ, T; Ford, J; Horvath, Z; Jost, N; Madge, D; Matschke, K; Milnes, J; Ravens, U; Rogers, M; Sutton, K; Varro, A; Virag, L; Wettwer, E	1
Grove, EL; Husted, SE; Kraglund, KL; Modrau, B	1
Brem, E; Foran, M; Koyfman, A	1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Mohanty, S; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Zhang, Z	1
Reynolds, MR	1
Contractor, T; Levin, V; Marchlinski, FE; Martinez, MW	1
Bauersachs, RM	1
Harenberg, J; Wehling, M	1
Califf, RM; Fox, KA; Mahaffey, KW; Patel, MR; Piccini, JP	1

Reviews

148 review(s) available for thiophenes and Atrial Fibrillation

Article	Year
Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:2 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Medication Adherence; Morpholines; Renal Insufficiency; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thromboembolism; Vitamin K; Warfarin	2013
Clinical management of rivaroxaban-treated patients. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:5 Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Consensus; Drug Interactions; Drug Substitution; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Medication Adherence; Morpholines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2013
Novel oral anticoagulants: a review of the literature and considerations in special clinical situations. Hospital practice (1995), 2013, Volume: 41, Issue:1 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Approval; Europe; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin	2013
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation. Hospital practice (1995), 2013, Volume: 41, Issue:1 Topics: Age Factors; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Comorbidity; Dabigatran; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyridines; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin	2013
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation. Hospital practice (1995), 2013, Volume: 41, Issue:1 Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice. Hospital practice (1995), 2013, Volume: 41, Issue:1 Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin	2013
[The role of internal medicine in preventing stroke in atrial fibrillation]. Medicina clinica, 2012, Volume: 139 Suppl 2 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Humans; Internal Medicine; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes	2012
[Advances in the secondary prevention of cardioembolic stroke]. Medicina clinica, 2012, Volume: 139 Suppl 2 Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Endovascular Procedures; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Spain; Stroke; Thiophenes	2012
Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly. Drugs & aging, 2013, Volume: 30, Issue:7 Topics: Aged; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin	2013
[Improvements in oral anticoagulant therapy for atrial fibrillation]. Medicina clinica, 2013, Dec-07, Volume: 141, Issue:11 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Warfarin	2013
Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care. International journal of clinical practice, 2013, Volume: 67, Issue:7 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Primary Health Care; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Workload	2013
[Factor Xa inhibitor (rivaroxaban and drugs under investigation)]. Nihon rinsho. Japanese journal of clinical medicine, 2013, Volume: 71, Issue:1 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thromboembolism	2013
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation. Contributions to nephrology, 2013, Volume: 179 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Disease Management; Embolism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Intracranial Embolism; Male; Morpholines; Patient Selection; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Warfarin	2013
Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Drugs, 2013, Volume: 73, Issue:7 Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Drug Interactions; Embolism; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes	2013
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. Annals of the New York Academy of Sciences, 2013, Volume: 1291 Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome	2013
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thrombosis and haemostasis, 2013, Volume: 110, Issue:2 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Endoscopy; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal. Stroke, 2013, Volume: 44, Issue:6 Suppl 1 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Prodrugs; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin	2013
Novel oral anticoagulants in gastroenterology practice. Gastrointestinal endoscopy, 2013, Volume: 78, Issue:2 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes	2013
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:24 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin	2013
Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants. Postgraduate medicine, 2013, Volume: 125, Issue:3 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes	2013
Pharmacokinetic considerations for antithrombotic therapies in stroke. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:10 Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Tetrazoles; Thiophenes; Thrombin; Ticlopidine; Vitamin K	2013
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. The Canadian journal of cardiology, 2013, Volume: 29, Issue:7 Suppl Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Humans; Morpholines; Outcome Assessment, Health Care; Patient Selection; Polymorphism, Genetic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2013, Volume: 16, Issue:4 Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cost-Benefit Analysis; Dabigatran; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Time Factors; Warfarin	2013
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. Heart failure reviews, 2014, Volume: 19, Issue:3 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug Monitoring; Heart Failure; Hemorrhage; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Warfarin	2014
Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012. Postgraduate medicine, 2013, Volume: 125, Issue:2 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin	2013
New alternative anticoagulants in atrial fibrillation: the move beyond warfarin. Reviews on recent clinical trials, 2013, Volume: 8, Issue:2 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Morpholines; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
What are the new therapeutic alternatives to warfarin in atrial fibrillation? JPMA. The Journal of the Pakistan Medical Association, 2013, Volume: 63, Issue:1 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pakistan; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
[New clinical perspectives in the management of oral direct anticoagulant agents]. Medicina clinica, 2014, Feb-20, Volume: 142, Issue:4 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Elective Surgical Procedures; Emergencies; Factor Xa Inhibitors; Hemorrhage; Humans; Kidney Diseases; Morpholines; Orthopedic Procedures; Postoperative Complications; Premedication; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiophenes; Thrombophilia; Vitamin K	2014
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. Clinical therapeutics, 2013, Volume: 35, Issue:7 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation. Neurologic clinics, 2013, Volume: 31, Issue:3 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes	2013
Novel oral anticoagulants: a review of new agents. Postgraduate medicine, 2013, Volume: 125, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Postoperative Complications; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis	2013
Novel oral anticoagulants in non-valvular atrial fibrillation. Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism	2013
Novel oral anticoagulants in secondary prevention of stroke. Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Guidelines as Topic; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin	2013
New oral anticoagulants in elderly patients. Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin	2013
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin	2013
Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Clinical pharmacology and therapeutics, 2014, Volume: 95, Issue:2 Topics: Algorithms; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Dosage Calculations; Humans; Morpholines; Pharmacogenetics; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin	2014
New oral anticoagulants--a review. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2013, Oct-01, Volume: 133, Issue:18 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis	2013
Anticoagulation management in nonvalvular atrial fibrillation: current and future directions. Polskie Archiwum Medycyny Wewnetrznej, 2013, Volume: 123, Issue:11 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Fibrinolytic Agents; Forecasting; Humans; Morpholines; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Hemorrhage; Premedication; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin	2013
[Prevention of stroke in patients with atrial fibrillation: a role of modern anticoagulants]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2013, Volume: 113, Issue:9 Pt 2 Topics: Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? The Annals of pharmacotherapy, 2013, Volume: 47, Issue:11 Topics: Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Benzimidazoles; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes	2013
Outpatient management of oral anticoagulation in atrial fibrillation. Critical care nursing clinics of North America, 2013, Volume: 25, Issue:4 Topics: Ambulatory Care; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
[Evidence of novel oral anticoagulants (NOAC)]. Rinsho shinkeigaku = Clinical neurology, 2013, Volume: 53, Issue:11 Topics: Administration, Ophthalmic; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Infarction; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban. Journal of thrombosis and thrombolysis, 2014, Volume: 38, Issue:2 Topics: Acute Coronary Syndrome; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism	2014
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Journal of clinical pharmacy and therapeutics, 2014, Volume: 39, Issue:2 Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes	2014
{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF. Drug and therapeutics bulletin, 2014, Volume: 52, Issue:1 Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes	2014
[New anticoagulants in patients with atrial fibrillation]. MMW Fortschritte der Medizin, 2013, May-02, Volume: 155, Issue:8 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Infarction; Dabigatran; Humans; Intracranial Embolism; Ischemic Attack, Transient; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K	2013
New oral anticoagulants in practice: pharmacological and practical considerations. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:3 Topics: Administration, Oral; Aging; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Complementary Therapies; Dabigatran; Drug Interactions; Drug Monitoring; Humans; International Normalized Ratio; Kidney Diseases; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin	2014
[Novel oral anticoagulants and atrial fibrillation in the elderly]. Geriatrie et psychologie neuropsychiatrie du vieillissement, 2013, Volume: 11, Issue:1 Suppl Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Drugs, Investigational; Half-Life; Humans; Intracranial Embolism; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Vitamin K	2013
Is there a role for novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials. Polskie Archiwum Medycyny Wewnetrznej, 2013, Volume: 123, Issue:11 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes	2013
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome. The American journal of cardiology, 2014, Mar-01, Volume: 113, Issue:5 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Ticlopidine	2014
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circulation. Cardiovascular interventions, 2014, Volume: 7, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Ticagrelor	2014
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Data Interpretation, Statistical; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome	2014
Practical aspects of new oral anticoagulant use in atrial fibrillation. Polskie Archiwum Medycyny Wewnetrznej, 2014, Volume: 124, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2014
[Prevention of embolic heart complications in atrial fibrillation: possibilities of using rivaroxaban]. Terapevticheskii arkhiv, 2013, Volume: 85, Issue:12 Topics: Anticoagulants; Atrial Fibrillation; Controlled Clinical Trials as Topic; Embolism; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin	2013
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vascular health and risk management, 2014, Volume: 10 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Drug Administration Schedule; Drug Interactions; Drug Substitution; Hemorrhage; Humans; Morpholines; Patient Selection; Perioperative Care; Practice Guidelines as Topic; Preventive Health Services; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome	2014
The role of rivaroxaban in atrial fibrillation and acute coronary syndromes. Journal of cardiovascular pharmacology and therapeutics, 2014, Volume: 19, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Atrial Fibrillation; Blood Coagulation; Cost-Benefit Analysis; Drug Costs; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome	2014
The newer direct oral anticoagulants: a practical guide. Clinical medicine (London, England), 2014, Volume: 14, Issue:2 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin	2014
Anticoagulation in atrial fibrillation. BMJ (Clinical research ed.), 2014, Apr-14, Volume: 348 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin	2014
Anticoagulation: a GP primer on the new oral anticoagulants. Australian family physician, 2014, Volume: 43, Issue:5 Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; General Practice; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin	2014
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all? Current vascular pharmacology, 2014, Volume: 12, Issue:3 Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Primary Prevention; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes	2014
Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 40, Issue:3 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Translational Research, Biomedical; Treatment Outcome	2014
[Gastrointestinal bleeding under treatment with new oral anticoagulants]. MMW Fortschritte der Medizin, 2014, Feb-06, Volume: 156, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Embolism; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K; Warfarin	2014
Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence. Expert review of cardiovascular therapy, 2014, Volume: 12, Issue:8 Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin	2014
Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. The American journal of cardiology, 2014, Aug-15, Volume: 114, Issue:4 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin	2014
NOAC and intracerebral bleeding--presentation of four cases and review of the literature. Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg, 2014, Issue:1 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Female; Humans; Hypertension; Male; Morpholines; Rivaroxaban; Thiophenes	2014
[Update on current care guideline: atrial fibrillation]. Duodecim; laaketieteellinen aikakauskirja, 2014, Volume: 130, Issue:12 Topics: Administration, Oral; Anti-Arrhythmia Agents; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Incidence; Morpholines; Practice Guidelines as Topic; Prevalence; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin	2014
[Treatment of very old patients with non valvular atrial fibrillation. The valuable opportunity offered by new oral anticoagulants, to be cautiously used]. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2013, Volume: 80, Issue:4 Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes	2013
Atrial fibrillation - new frontiers in anticoagulation. Cardiovascular & hematological disorders drug targets, 2014, Volume: 14, Issue:1 Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes	2014
Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation. Cardiovascular & hematological disorders drug targets, 2014, Volume: 14, Issue:1 Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Discovery; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin	2014
Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs, 2014, Volume: 74, Issue:14 Topics: Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hip Joint; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism	2014
Oral anticoagulants for stroke prevention in atrial fibrillation. Current problems in cardiology, 2014, Volume: 39, Issue:9 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Drug Therapy, Combination; Humans; Morpholines; Patient Preference; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes	2014
Target-specific oral anticoagulants: practice issues for the clinician. Hospital practice (1995), 2014, Volume: 42, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin	2014
Switching between oral anticoagulants. Hospital practice (1995), 2014, Volume: 42, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; United States; Warfarin	2014
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation. International journal of clinical pharmacology and therapeutics, 2015, Volume: 53, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Patient Safety; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism	2015
[Stroke prevention after stroke in patients with atrial fibrillation: a case-based review]. Orvosi hetilap, 2014, Oct-19, Volume: 155, Issue:42 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin	2014
Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nature reviews. Cardiology, 2014, Volume: 11, Issue:12 Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism	2014
Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Canadian family physician Medecin de famille canadien, 2014, Volume: 60, Issue:11 Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin	2014
Novel oral anticoagulants in non-valvular atrial fibrillation. Cardiovascular & hematological agents in medicinal chemistry, 2014, Volume: 12, Issue:1 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemistry, Pharmaceutical; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes	2014
[More with atrial fibrillation, anticoagulants since the coming of NOAK ]. Lakartidningen, 2015, Jan-06, Volume: 112 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Drug Prescriptions; Drug Utilization; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin	2015
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? Annual review of medicine, 2015, Volume: 66 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin	2015
The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials. American heart journal, 2015, Volume: 169, Issue:3 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome	2015
Overview of the new oral anticoagulants: opportunities and challenges. Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:5 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin	2015
[Prophylaxis of thromboembolism in atrial fibrillation: new oral anticoagulants and left atrial appendage closure]. Deutsche medizinische Wochenschrift (1946), 2015, Volume: 140, Issue:16 Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Combined Modality Therapy; Contraindications; Dabigatran; Hemorrhage; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K	2015
Brave new world: the current and future use of novel anticoagulants. Thrombosis research, 2008, Volume: 123 Suppl 1 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism	2008
Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism. Current vascular pharmacology, 2010, Volume: 8, Issue:1 Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Fondaparinux; Humans; Morpholines; Polysaccharides; Rivaroxaban; Thiophenes; Venous Thromboembolism	2010
New anticoagulants for atrial fibrillation. Seminars in thrombosis and hemostasis, 2009, Volume: 35, Issue:5 Topics: Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; Biotin; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K	2009
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Current opinion in cardiology, 2010, Volume: 25, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Benzamides; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin	2010
[New oral anticoagulants: better than vitamin K antagonists?]. Der Internist, 2010, Volume: 51, Issue:12 Topics: Anticoagulants; Antithrombin Proteins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis; Vitamin K	2010
[Novel anticoagulants for stroke prevention in atrial fibrillation]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:46 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism	2010
[New study findings in cardiology. The best is the enemy of the good]. Medizinische Monatsschrift fur Pharmazeuten, 2010, Volume: 33, Issue:11 Topics: Angioplasty, Balloon, Coronary; Angiotensin II Type 2 Receptor Blockers; Anticoagulants; Atrial Fibrillation; Cardiology; Coronary Disease; Drug-Eluting Stents; Heart Diseases; Humans; Morpholines; Myocardial Infarction; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K	2010
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annual review of medicine, 2011, Volume: 62 Topics: Acute Coronary Syndrome; Amidines; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Treatment Outcome; Vitamin K	2011
Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K	2011
Triple therapy in hospitalized patients: facts and controversies. Journal of hospital medicine, 2011, Volume: 6, Issue:9 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hospitalization; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Warfarin	2011
Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes. Expert opinion on investigational drugs, 2011, Volume: 20, Issue:4 Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drugs, Investigational; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Venous Thromboembolism	2011
New anticoagulants: pharmacology and clinical studies. Wiener medizinische Wochenschrift (1946), 2011, Volume: 161, Issue:3-4 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prothrombin; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2011
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. European heart journal, 2011, Volume: 32, Issue:16 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Approval; Factor X; Humans; Morpholines; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism	2011
[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future]. Medecine sciences : M/S, 2011, Volume: 27, Issue:5 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Approval; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Forecasting; France; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Thrombophilia; Venous Thromboembolism	2011
[The new Anticoagulants - Relevant Facts for the GP]. Praxis, 2011, Aug-10, Volume: 100, Issue:16 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Factor Xa Inhibitors; General Practice; Humans; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2011
Rivaroxaban (Xarelto)--a new oral anticoagulant. The Medical letter on drugs and therapeutics, 2011, Aug-22, Volume: 53, Issue:1371 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thrombosis	2011
[Thromboembolic prophylaxis 2011: is warfarin on the wane?]. Giornale italiano di cardiologia (2006), 2011, Volume: 12, Issue:9 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin	2011
[Atrial fibrillation: what the GP needs to know]. MMW Fortschritte der Medizin, 2011, Sep-22, Volume: 153, Issue:38 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; General Practice; Humans; International Normalized Ratio; Medication Adherence; Morpholines; Partial Thromboplastin Time; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes	2011
[New anticoagulants. Characteristics, monitoring and management of bleeding]. Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2011, Volume: 106, Issue:3 Topics: Administration, Oral; Antithrombins; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; Blood Coagulation Tests; Critical Care; Dabigatran; Drug Approval; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombophilia; Vitamin K	2011
A new era of antithrombotic therapy in patients with atrial fibrillation. The American journal of the medical sciences, 2012, Volume: 344, Issue:2 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
[Current status and future of anti-Xa inhibitors]. Rinsho shinkeigaku = Clinical neurology, 2011, Volume: 51, Issue:11 Topics: Anticoagulants; Atrial Fibrillation; Azepines; Benzamides; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes	2011
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease. Expert review of neurotherapeutics, 2012, Volume: 12, Issue:2 Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes	2012
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation? Cardiology journal, 2012, Volume: 19, Issue:1 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin	2012
A new generation of oral direct anticoagulants. Arteriosclerosis, thrombosis, and vascular biology, 2012, Volume: 32, Issue:3 Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome	2012
A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation? Polskie Archiwum Medycyny Wewnetrznej, 2012, Volume: 122, Issue:1-2 Topics: Anticoagulants; Atrial Fibrillation; Drugs, Investigational; Factor X; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Vitamin K; Warfarin	2012
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2012, Volume: 18, Issue:5 Topics: Acute Coronary Syndrome; Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin	2012
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation. Journal of internal medicine, 2012, Volume: 271, Issue:6 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drugs, Investigational; Heparin; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K	2012
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. The American journal of cardiology, 2012, Aug-01, Volume: 110, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
Novel oral anticoagulants--key messages for the angiologist. VASA. Zeitschrift fur Gefasskrankheiten, 2012, Volume: 41, Issue:3 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Predictive Value of Tests; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism	2012
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation. Critical pathways in cardiology, 2012, Volume: 11, Issue:2 Topics: Anticoagulants; Antithrombin Proteins; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; Chemoprevention; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin	2012
Breakthroughs in anticoagulation: advent of the oral direct factor Xa inhibitors. Journal of cardiothoracic and vascular anesthesia, 2012, Volume: 26, Issue:4 Topics: Acute Coronary Syndrome; Anesthesia, Conduction; Animals; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2012
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2012, Volume: 35, Issue:1 Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin	2012
[Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?]. MMW Fortschritte der Medizin, 2012, Mar-22, Volume: 154, Issue:5 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Factor Xa Inhibitors; Guideline Adherence; Hemorrhage; Humans; Intracranial Embolism; Morpholines; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes	2012
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Advances in therapy, 2012, Volume: 29, Issue:6 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thrombosis and haemostasis, 2012, Volume: 108, Issue:3 Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin	2012
New oral anticoagulants for atrial fibrillation. Circulation, 2012, Jul-03, Volume: 126, Issue:1 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Substitution; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pyridines; Rivaroxaban; Thiophenes	2012
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:10 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Comparative Effectiveness Research; Dabigatran; Drug Monitoring; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Outcome and Process Assessment, Health Care; Pharmacovigilance; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
New oral anticoagulants in the ED setting: a review. The American journal of emergency medicine, 2012, Volume: 30, Issue:9 Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism	2012
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. International angiology : a journal of the International Union of Angiology, 2012, Volume: 31, Issue:4 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chi-Square Distribution; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Odds Ratio; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome	2012
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:10 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Preventive Health Services; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2012
Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges. Current medicinal chemistry, 2012, Volume: 19, Issue:27 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Benzoates; Clinical Trials as Topic; Coumarins; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Warfarin	2012
Clinical considerations of anticoagulation therapy for patients with atrial fibrillation. Journal of Zhejiang University. Science. B, 2012, Volume: 13, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiology; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation. Minerva cardioangiologica, 2012, Volume: 60, Issue:4 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2012
Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome. Future cardiology, 2012, Volume: 8, Issue:4 Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drug Approval; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin	2012
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed. Canadian family physician Medecin de famille canadien, 2012, Volume: 58, Issue:8 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
Stroke prevention in atrial fibrillation: concepts and controversies. Current cardiology reviews, 2012, Volume: 8, Issue:4 Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Dronedarone; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2012
[The new anticoagulants - their role in secondary prevention of thromboembolism after stroke]. Therapeutische Umschau. Revue therapeutique, 2012, Volume: 69, Issue:9 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K	2012
New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Oct-01, Volume: 12, Issue:5 Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
[New oral anticoagulants for atrial fibrillation: a neurologist's view]. Nederlands tijdschrift voor geneeskunde, 2012, Volume: 156, Issue:39 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes	2012
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. Thrombosis and haemostasis, 2012, Volume: 108, Issue:5 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pregnancy; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin	2012
What did we learn from new oral anticoagulant treatment? Thrombosis research, 2012, Volume: 130 Suppl 1 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Half-Life; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis	2012
Antithrombotic treatment of atrial fibrillation: new insights. Thrombosis research, 2012, Volume: 130 Suppl 1 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K	2012
Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial. Expert review of cardiovascular therapy, 2012, Volume: 10, Issue:8 Topics: Anticoagulants; Atrial Fibrillation; Gastrointestinal Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation]. Kardiologia polska, 2012, Volume: 70, Issue:10 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Humans; Kidney Failure, Chronic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin	2012
[Stroke risk--atrial fibrillation]. MMW Fortschritte der Medizin, 2012, Nov-01, Volume: 154, Issue:19 Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sectional Studies; Dabigatran; Humans; International Normalized Ratio; Minimally Invasive Surgical Procedures; Morpholines; Population Dynamics; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes	2012
The novel anticoagulants: the surgeons' prospective. Surgery, 2013, Volume: 153, Issue:3 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surgical Procedures, Operative; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin	2013
New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures. Internal and emergency medicine, 2013, Volume: 8, Issue:2 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis	2013
[Rivaroxaban in prevention of stroke in patients with atrial fibrillation]. Ideggyogyaszati szemle, 2012, Nov-30, Volume: 65, Issue:11-12 Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Administration Schedule; Humans; International Normalized Ratio; Morpholines; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome	2012
A review of oral anticoagulants in patients with atrial fibrillation. Postgraduate medicine, 2012, Volume: 124, Issue:6 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
Rivaroxaban: an oral factor Xa inhibitor. Clinical therapeutics, 2013, Volume: 35, Issue:1 Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism	2013
[Anticoagulant therapy in stroke patients]. Ugeskrift for laeger, 2013, Jan-28, Volume: 175, Issue:5 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Radiography; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K	2013
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians. The Journal of emergency medicine, 2013, Volume: 45, Issue:1 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emergencies; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin	2013
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era. Postgraduate medicine, 2013, Volume: 125, Issue:1 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes	2013
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Seminars in thrombosis and hemostasis, 2008, Volume: 34, Issue:1 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Glycine; Humans; Infusions, Parenteral; Morpholines; Oligosaccharides; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Venous Thromboembolism	2008
Rivaroxaban, an oral direct factor Xa inhibitor. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Animals; Anticoagulants; Atrial Fibrillation; Binding Sites; Clinical Trials as Topic; Comorbidity; Drug Evaluation, Preclinical; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Rats; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Warfarin	2008

Trials

51 trial(s) available for thiophenes and Atrial Fibrillation

Article	Year
[Rivaroxaban in prevention of stroke in elderly patients with non-valvular atrial fibrillation]. Kardiologiia, 2019, Nov-17, Volume: 59, Issue:12S Topics: Aged; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome	2019
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. Journal of the American College of Cardiology, 2013, May-14, Volume: 61, Issue:19 Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Electric Countershock; Female; Humans; Male; Middle Aged; Morpholines; Multicenter Studies as Topic; Multivariate Analysis; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2013
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. Journal of the American Heart Association, 2013, Feb-19, Volume: 2, Issue:1 Topics: Aged; Anticoagulants; Asia; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Drug Monitoring; Europe; Female; Healthcare Disparities; Humans; International Normalized Ratio; Linear Models; Male; Morpholines; Multivariate Analysis; North America; Predictive Value of Tests; Residence Characteristics; Rivaroxaban; South Africa; South America; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin	2013
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circulation. Heart failure, 2013, Volume: 6, Issue:4 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Heart Failure; Humans; Intention to Treat Analysis; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Warfarin	2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. Circulation. Cardiovascular quality and outcomes, 2013, Volume: 6, Issue:4 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Clinical Protocols; Continuity of Patient Care; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Embolism; Factor Xa; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; Proportional Hazards Models; Research Design; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Vitamin K; Warfarin	2013
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Annals of internal medicine, 2013, Jun-18, Volume: 158, Issue:12 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin	2013
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. Clinical therapeutics, 2013, Volume: 35, Issue:7 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation. Vascular, 2014, Volume: 22, Issue:4 Topics: Administration, Oral; Aged; Anticoagulants; Asian People; Atrial Fibrillation; China; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Male; Morpholines; Primary Prevention; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin	2014
Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:2 Topics: Aged; Anticoagulants; Asian People; Atrial Fibrillation; Disease-Free Survival; Double-Blind Method; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Morpholines; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin	2014
A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation. Clinical drug investigation, 2013, Volume: 33, Issue:11 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes	2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. European heart journal, 2014, Volume: 35, Issue:4 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Female; Humans; Kaplan-Meier Estimate; Male; Morpholines; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin	2014
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. European heart journal, 2014, Volume: 35, Issue:4 Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Humans; Male; Morpholines; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2014
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). Journal of the American College of Cardiology, 2014, Mar-11, Volume: 63, Issue:9 Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Pressure; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Vitamin K; Warfarin	2014
Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thrombosis and haemostasis, 2014, Volume: 111, Issue:6 Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Cross-Sectional Studies; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Partial Thromboplastin Time; Point-of-Care Systems; Prothrombin Time; Reference Values; Rivaroxaban; Thiophenes; Venous Thromboembolism; Whole Blood Coagulation Time	2014
Rivaroxaban in clinical practice for atrial fibrillation with special reference to prothrombin time. Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:3 Topics: Aged; Aged, 80 and over; Asian People; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Japan; Male; Middle Aged; Morpholines; Prospective Studies; Prothrombin Time; Rivaroxaban; Thiophenes	2014
Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial. Hypertension research : official journal of the Japanese Society of Hypertension, 2014, Volume: 37, Issue:5 Topics: Aged; Asian People; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Hypertension; Japan; Male; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Warfarin	2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stro Circulation, 2014, May-06, Volume: 129, Issue:18 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Intracranial Embolism; Male; Morpholines; Proportional Hazards Models; Prospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin	2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. European heart journal, 2014, Jul-21, Volume: 35, Issue:28 Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Blood Transfusion; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Hospitalization; Humans; Male; Morpholines; Plasma; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin	2014
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. Journal of clinical pharmacology, 2014, Volume: 54, Issue:8 Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; Morpholines; Prothrombin Time; Renal Insufficiency; Rivaroxaban; Thiophenes	2014
Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age. Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:6 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Risk Factors; Rivaroxaban; Thiophenes; Warfarin	2014
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in at Stroke, 2014, Volume: 45, Issue:5 Topics: Aged; Anticoagulants; Asian People; Atrial Fibrillation; Black People; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Morpholines; Prospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin	2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. Journal of the American Heart Association, 2014, Apr-22, Volume: 3, Issue:2 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Drug Monitoring; Embolism; Europe; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; North America; Point-of-Care Systems; Predictive Value of Tests; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin	2014
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban onc American heart journal, 2014, Volume: 167, Issue:5 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography, Transesophageal; Electric Countershock; Embolism; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Morpholines; Prospective Studies; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Vitamin K	2014
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. Heart rhythm, 2014, Volume: 11, Issue:6 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome	2014
Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2014, Volume: 20, Issue:7 Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medical Records Systems, Computerized; Middle Aged; Morpholines; Rivaroxaban; Thiophenes	2014
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Circulation, 2014, Jul-08, Volume: 130, Issue:2 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin	2014
Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 41, Issue:2 Topics: Adult; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Patient Safety; Postoperative Care; Preoperative Care; Prospective Studies; Pulmonary Embolism; Rivaroxaban; Statistics, Nonparametric; Survival Rate; Thiophenes; Treatment Outcome; Venous Thrombosis; Vitamin K; Warfarin	2014
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vascular health and risk management, 2014, Volume: 10 Topics: Africa; Atrial Fibrillation; Clinical Protocols; Europe; Factor Xa Inhibitors; Humans; Latin America; Middle East; Morpholines; Prospective Studies; Research Design; Risk Assessment; Risk Factors; Rivaroxaban; Sample Size; Stroke; Thiophenes; Time Factors; Treatment Outcome	2014
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. European heart journal, 2014, Dec-14, Volume: 35, Issue:47 Topics: Aged; Anticoagulants; Aortic Valve Insufficiency; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Mitral Valve Insufficiency; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2014
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. European heart journal, 2014, Dec-14, Volume: 35, Issue:47 Topics: Administration, Oral; Aged; Atrial Fibrillation; Electric Countershock; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K	2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. European heart journal, 2015, Feb-01, Volume: 36, Issue:5 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cause of Death; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Morpholines; Prospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin	2015
Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation. International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:1 Topics: Adult; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Research Design; Rivaroxaban; Stroke; Thiophenes	2015
[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2014, Volume: 37, Issue:221 Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Diseases; Hemorrhage; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism	2014
Dose-finding study of rivaroxaban in hemodialysis patients. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015, Volume: 66, Issue:1 Topics: Administration, Oral; Area Under Curve; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Female; Half-Life; Hemorrhage; Humans; Kidney Failure, Chronic; Male; Morpholines; Renal Dialysis; Rivaroxaban; Thiophenes; Thromboembolism; Thrombophilia	2015
Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry prov American heart journal, 2015, Volume: 169, Issue:4 Topics: Administration, Oral; Atrial Appendage; Atrial Fibrillation; Catheter Ablation; Dose-Response Relationship, Drug; Drug Administration Schedule; Echocardiography, Transesophageal; Electric Countershock; Factor Xa Inhibitors; Female; Heart Diseases; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome	2015
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention American heart journal, 2015, Volume: 169, Issue:4 Topics: Administration, Oral; Aged; Atrial Fibrillation; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Rivaroxaban; Thiophenes; Ticlopidine; Treatment Outcome; Vitamin K	2015
Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban. Annals of hematology, 2015, Volume: 94, Issue:9 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa; Factor Xa Inhibitors; Female; Heparin; Humans; Male; Morpholines; Prothrombin Time; Rivaroxaban; Stroke; Thiophenes	2015
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. American heart journal, 2010, Volume: 159, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Drug Administration Schedule; Embolism; Factor Xa Inhibitors; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Medical Records; Morpholines; Research Design; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin	2010
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England journal of medicine, 2011, Sep-08, Volume: 365, Issue:10 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Intention to Treat Analysis; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2011
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. European heart journal, 2011, Volume: 32, Issue:19 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Male; Morpholines; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2011
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clinical pharmacokinetics, 2011, Volume: 50, Issue:10 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Body Weight; Computer Simulation; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis; Young Adult	2011
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. The Lancet. Neurology, 2012, Volume: 11, Issue:4 Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Humans; Intention to Treat Analysis; Ischemic Attack, Transient; Morpholines; Multicenter Studies as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Treatment Outcome; Warfarin	2012
Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Morpholines; Prospective Studies; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug metabolism and pharmacokinetics, 2013, Volume: 28, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Area Under Curve; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Models, Biological; Morpholines; Partial Thromboplastin Time; Patient Simulation; Prothrombin Time; Rivaroxaban; Thiophenes	2013
Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. Thrombosis and haemostasis, 2012, Volume: 108, Issue:6 Topics: Aged; Anticoagulants; Atrial Fibrillation; Biomarkers; Blood Proteins; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Proteomics; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Warfarin	2012
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K ant Circulation, 2013, Jan-15, Volume: 127, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa; Female; Follow-Up Studies; Humans; Incidence; Male; Morpholines; Predictive Value of Tests; Reproducibility of Results; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin	2013
Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Japan; Kidney; Male; Middle Aged; Morpholines; Renal Insufficiency; Reproducibility of Results; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2013
Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients. Drug metabolism and pharmacokinetics, 2013, Volume: 28, Issue:4 Topics: Asian People; Atrial Fibrillation; Dose-Response Relationship, Drug; Humans; Models, Biological; Morpholines; Rivaroxaban; Thiophenes	2013
Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:8 Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Morpholines; Prospective Studies; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Treatment Outcome; Warfarin	2013
Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. Journal of cardiovascular pharmacology, 2013, Volume: 61, Issue:5 Topics: Action Potentials; Atrial Fibrillation; Atrial Function; Cell Line; Double-Blind Method; Electrocardiography; Heart Atria; Humans; In Vitro Techniques; Kv1.5 Potassium Channel; Male; Myocardial Contraction; Myocytes, Cardiac; Potassium; Potassium Channel Blockers; Pyrimidines; Thiophenes; Ventricular Function	2013
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention o Journal of the American College of Cardiology, 2013, Feb-12, Volume: 61, Issue:6 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Morpholines; Outcome Assessment, Health Care; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Time Factors; Warfarin; Withholding Treatment	2013

Other Studies

184 other study(ies) available for thiophenes and Atrial Fibrillation

Article	Year
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. Journal of the American Heart Association, 2021, 10-05, Volume: 10, Issue:19 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Humans; Intention to Treat Analysis; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome	2021
Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation. Acta pharmacologica Sinica, 2022, Volume: 43, Issue:10 Topics: Anticoagulants; Atrial Fibrillation; Bilirubin; China; Factor Xa Inhibitors; Humans; Morpholines; Nucleotides; Prospective Studies; Rivaroxaban; Stroke; Thiophenes	2022
Present status and future orientation of rivaroxaban application in patients with nonvulvular atrial fibrillation. Thrombosis research, 2017, Volume: 156 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin	2017
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation. Hospital practice (1995), 2013, Volume: 41, Issue:1 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
Rivaroxaban modulates electrical and mechanical characteristics of left atrium. Journal of biomedical science, 2013, Mar-15, Volume: 20 Topics: Action Potentials; Animals; Atrial Fibrillation; Calcium; Heart Atria; Humans; Ion Transport; Male; Microelectrodes; Morpholines; Myocytes, Cardiac; Patch-Clamp Techniques; Potassium Channels, Voltage-Gated; Pulmonary Veins; Rabbits; Rivaroxaban; Thiophenes	2013
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke, 2013, Volume: 44, Issue:6 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Humans; Markov Chains; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin	2013
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)]. MMW Fortschritte der Medizin, 2013, Feb-21, Volume: 155, Issue:3 Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Fibrinolytic Agents; Guideline Adherence; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. Clinical pharmacology and therapeutics, 2013, Volume: 94, Issue:2 Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Comorbidity; Computer Simulation; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Time Factors; Warfarin	2013
[Stroke prevention in atrial fibrillation : old and new anticoagulants]. Herz, 2013, Volume: 38, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K	2013
Conventional and new oral anticoagulants in the treatment of chest disease and its complications. American journal of respiratory and critical care medicine, 2013, Aug-15, Volume: 188, Issue:4 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Practice Guidelines as Topic; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K	2013
Summaries for patients. Rivaroxaban in patients transitioned from vitamin K antagonist therapy. Annals of internal medicine, 2013, Jun-18, Volume: 158, Issue:12 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin	2013
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation". Thrombosis and haemostasis, 2013, Volume: 110, Issue:3 Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Patient Safety; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin	2013
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.". Thrombosis and haemostasis, 2013, Volume: 110, Issue:3 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin	2013
Ask the doctors. I have atrial fibrillation and have been taking warfarin to prevent blood clots for 10 years. It has not given me any problems. However, I do hate going to my doctor's office to get my INR blood test every month. I'm wondering whether Harvard heart letter : from Harvard Medical School, 2013, Volume: 23, Issue:5 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation Tests; Health Behavior; Humans; Morpholines; Pyrazoles; Pyridines; Thiophenes; Warfarin	2013
[Comparison of the therapeutic effect of the Warfarin and Rivaroksaban among the patients with not-valuate fibrillation of atrium]. Georgian medical news, 2013, Issue:219 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2013
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials. Journal of medical economics, 2013, Volume: 16, Issue:9 Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Savings; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Utilization; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; United States; Warfarin	2013
The J-ROCKET AF study: a matter of ethnicity or a matter of weight? Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:10 Topics: Anticoagulants; Atrial Fibrillation; Embolism; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Warfarin	2013
The J-ROCKET AF Study: a matter of ethnicity or a matter of weight? Reply. Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:10 Topics: Anticoagulants; Atrial Fibrillation; Embolism; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Warfarin	2013
Should the newer oral anticoagulants be withheld from patients with valvular AF? Chest, 2013, Volume: 144, Issue:2 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; International Normalized Ratio; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers. Journal of medical economics, 2013, Volume: 16, Issue:10 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
The promise of pharmacoepidemiology in helping clinicians assess drug risk. Circulation, 2013, Aug-13, Volume: 128, Issue:7 Topics: Administration, Oral; Advertising; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confounding Factors, Epidemiologic; Dabigatran; Decision Making; Evidence-Based Medicine; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pharmacoepidemiology; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rivaroxaban; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Warfarin	2013
[Differential therapy with the new anticoagulants, 5]. MMW Fortschritte der Medizin, 2013, May-16, Volume: 155, Issue:9 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Germany; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes	2013
New oral anticoagulants for non-valvular atrial fibrillation--safety issues. Irish medical journal, 2013, Volume: 106, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome	2013
Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Fact Circulation, 2013, Sep-10, Volume: 128, Issue:11 Topics: Atrial Fibrillation; Embolism; Factor Xa; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Vitamin K	2013
Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inh Circulation, 2013, Sep-10, Volume: 128, Issue:11 Topics: Atrial Fibrillation; Embolism; Factor Xa; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Vitamin K	2013
Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. PharmacoEconomics, 2013, Volume: 31, Issue:10 Topics: Anticoagulants; Atrial Fibrillation; Belgium; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Humans; Markov Chains; Morpholines; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:1 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Models, Economic; Morpholines; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Warfarin	2014
A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation. Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health, 2013, Volume: 72, Issue:9 Suppl 4 Topics: Aged, 80 and over; Anticoagulants; Arginine; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Glomerular Filtration Rate; Hawaii; Humans; Male; Morpholines; Pipecolic Acids; Retrospective Studies; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin	2013
Percutaneous left atrial appendage occlusion with a Watchman device following recurrent stroke on warfarin and rivaroxaban in patient with paroxysmal atrial fibrillation. Heart, lung & circulation, 2014, Volume: 23, Issue:2 Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiac Catheterization; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin	2014
Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs. European journal of clinical pharmacology, 2014, Volume: 70, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Utilization; Female; Humans; Male; Middle Aged; Morpholines; Practice Patterns, Physicians'; Rivaroxaban; Spain; Thiophenes	2014
Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Clinical drug investigation, 2014, Volume: 34, Issue:1 Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Factor Xa Inhibitors; Health Care Costs; Humans; Italy; Markov Chains; Morpholines; Pyrazoles; Pyridones; Quality of Life; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2014
Dissolution of the left atrial appendage thrombus with rivaroxaban therapy. Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 36, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Female; Humans; Male; Morpholines; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thrombosis; Treatment Outcome	2013
Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circulation. Cardiovascular quality and outcomes, 2013, Volume: 6, Issue:6 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; United States; Warfarin	2013
[Prevention and therapy of thromboembolism: rivaroxaban - better outcome - risk profile as standard therapy]. MMW Fortschritte der Medizin, 2013, Sep-12, Volume: 155, Issue:15 Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Substitution; Factor Xa Inhibitors; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Warfarin	2013
New oral anticoagulants: an emergency department overview. Emergency medicine Australasia : EMA, 2013, Volume: 25, Issue:6 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis	2013
Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? Current medical research and opinion, 2014, Volume: 30, Issue:4 Topics: Aged; Anticoagulants; Atrial Fibrillation; Female; Humans; Length of Stay; Male; Middle Aged; Morpholines; Retrospective Studies; Rivaroxaban; Thiophenes; Warfarin	2014
Inaccuracy of point-of-care international normalized ratio in rivaroxaban-treated patients. The Annals of pharmacotherapy, 2013, Volume: 47, Issue:9 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Humans; International Normalized Ratio; Male; Morpholines; Point-of-Care Systems; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thrombosis	2013
Atrial fibrillation and prior MI: searching for balance in ischaemic and bleeding events in patients treated with factor-specific anticoagulants. European heart journal, 2014, Volume: 35, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Warfarin	2014
[How to properly use warfarin and new anticoagulants]. Rinsho shinkeigaku = Clinical neurology, 2013, Volume: 53, Issue:11 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Humans; International Normalized Ratio; Morpholines; Practice Guidelines as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
New oral anticoagulants: their role and future. Clinical medicine (London, England), 2013, Volume: 13 Suppl 6 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin	2013
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Automation, Laboratory; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Equipment and Supplies; Factor VII; Hemorrhage; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Stroke; Thiophenes; Thrombelastography; Thrombin; Thrombin Time; Venous Thrombosis; Withholding Treatment	2014
Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. Journal of the American College of Cardiology, 2014, Mar-18, Volume: 63, Issue:10 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Perioperative Period; Postoperative Complications; Prospective Studies; Registries; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome	2014
Anticoagulation therapy: rivaroxaban is a safe and feasible alternative to warfarin in AF ablation. Nature reviews. Cardiology, 2014, Volume: 11, Issue:3 Topics: Atrial Fibrillation; Catheter Ablation; Female; Humans; Male; Morpholines; Thiophenes; Thromboembolism	2014
Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:7 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Pacing, Artificial; Dabigatran; Defibrillators, Implantable; Electric Countershock; Female; Germany; Hematoma; Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Pacemaker, Artificial; Prospective Studies; Prosthesis Design; Prosthesis Implantation; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome	2014
Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring. Haematologica, 2014, Volume: 99, Issue:2 Topics: Aged; Antibiotics, Antitubercular; Anticoagulants; Atrial Fibrillation; Ciprofloxacin; Coronary Artery Bypass; Drug Incompatibility; Female; Humans; Morpholines; Rifampin; Rivaroxaban; Thiophenes	2014
Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:2 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K; Warfarin	2014
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clinical therapeutics, 2014, Feb-01, Volume: 36, Issue:2 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Markov Chains; Models, Economic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome	2014
Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:8 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Prescriptions; Drug Utilization Review; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Portugal; Practice Patterns, Physicians'; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome	2014
Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. The American journal of cardiology, 2014, Apr-15, Volume: 113, Issue:8 Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Echocardiography, Transesophageal; Electric Countershock; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Morpholines; Retrospective Studies; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome	2014
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiazoles; Thiophenes; Treatment Outcome	2014
Spontaneus splenic rupture in a patient treated with rivaroxaban. The American journal of emergency medicine, 2014, Volume: 32, Issue:8 Topics: Abdominal Pain; Aged; Anticoagulants; Atrial Fibrillation; Emergency Service, Hospital; Humans; Male; Morpholines; Rivaroxaban; Rupture, Spontaneous; Shock, Hemorrhagic; Splenic Diseases; Stroke; Thiophenes	2014
Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 40, Issue:1 Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pulmonary Veins; Retrospective Studies; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin	2014
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Current medical research and opinion, 2014, Volume: 30, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Propensity Score; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin; Young Adult	2014
Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome. Thrombosis and haemostasis, 2014, Volume: 112, Issue:2 Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Biological Availability; Blood Coagulation; Dabigatran; Drug Monitoring; Drug Substitution; Factor Xa Inhibitors; Female; Humans; Infarction, Middle Cerebral Artery; Intestinal Absorption; Morpholines; Predictive Value of Tests; Pyridines; Risk Factors; Rivaroxaban; Short Bowel Syndrome; Thiophenes; Treatment Outcome	2014
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. PharmacoEconomics, 2014, Volume: 32, Issue:6 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Humans; Markov Chains; Models, Statistical; Morpholines; Norway; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin	2014
Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation? Current medical research and opinion, 2014, Volume: 30, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Databases, Factual; Female; Hospital Costs; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Morpholines; Propensity Score; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin; Young Adult	2014
A cost-analysis model for anticoagulant treatment in the hospital setting. Journal of medical economics, 2014, Volume: 17, Issue:7 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Factor Xa Inhibitors; Humans; Inpatients; Length of Stay; Models, Economic; Morpholines; Pulmonary Embolism; Randomized Controlled Trials as Topic; Retrospective Studies; Rivaroxaban; Thiophenes; United States; Venous Thrombosis; Warfarin	2014
Perioperative management of patients on new oral anticoagulants. The British journal of surgery, 2014, Volume: 101, Issue:7 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Elective Surgical Procedures; Emergencies; Half-Life; Hemorrhage; Humans; Medication Adherence; Morpholines; Preoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Time Factors; Warfarin	2014
Pseudo-ventricular tachycardia mimicking malignant arrhythmia in a patient with rapid atrial fibrillation. American journal of critical care : an official publication, American Association of Critical-Care Nurses, 2014, Volume: 23, Issue:3 Topics: Adrenergic beta-1 Receptor Antagonists; Artifacts; Atrial Fibrillation; Bisoprolol; Diagnosis, Differential; Diagnostic Errors; Electrocardiography; Factor Xa Inhibitors; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Tachycardia, Ventricular; Thiophenes; Treatment Outcome; Unnecessary Procedures	2014
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. Journal of medical economics, 2014, Volume: 17, Issue:8 Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparative Effectiveness Research; Cost-Benefit Analysis; Dabigatran; Factor Xa Inhibitors; Female; France; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin	2014
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. The American journal of medicine, 2014, Volume: 127, Issue:11 Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Drug Utilization Review; Factor Xa Inhibitors; Fees, Pharmaceutical; Female; Humans; Income; Male; Middle Aged; Morpholines; Multivariate Analysis; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Sex Factors; Stroke; Thiophenes; United States; Vitamin K; Warfarin; Young Adult	2014
Direct oral anticoagulants in atrial fibrillation. Seminars in hematology, 2014, Volume: 51, Issue:2 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin	2014
Atrial fibrillation and stroke prevention in aging patients: what's good can be even better. Circulation, 2014, Jul-08, Volume: 130, Issue:2 Topics: Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin	2014
Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Current medical research and opinion, 2014, Volume: 30, Issue:12 Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Databases, Factual; Female; Humans; Male; Medication Adherence; Middle Aged; Morpholines; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin	2014
Measurement of rivaroxaban and apixaban in serum samples of patients. European journal of clinical investigation, 2014, Volume: 44, Issue:8 Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Biological Assay; Case-Control Studies; Chromogenic Compounds; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Serum; Specimen Handling; Thiophenes; Thromboembolism	2014
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? Clinical pharmacology and therapeutics, 2014, Volume: 96, Issue:1 Topics: Administration, Oral; Anticoagulants; Antithrombins; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP2C9; Dabigatran; Factor Xa Inhibitors; Genotype; Humans; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Vitamin K Epoxide Reductases; Warfarin	2014
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis. Internal medicine journal, 2014, Volume: 44, Issue:6 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Blood Loss, Surgical; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Elective Surgical Procedures; Emergencies; Hematoma, Epidural, Spinal; Hemorrhage; Humans; Kidney Diseases; Liver Diseases; Morpholines; Patient Selection; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombophilia	2014
Letter to the editor concerning the rationale and design of the X-VERT trial by Ezekowitz et al. American heart journal, 2014, Volume: 168, Issue:1 Topics: Atrial Fibrillation; Electric Countershock; Embolism; Female; Humans; Male; Morpholines; Thiophenes; Vitamin K	2014
Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures. Circulation. Arrhythmia and electrophysiology, 2014, Volume: 7, Issue:4 Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Chi-Square Distribution; Drug Administration Schedule; Female; Germany; Heart Atria; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Morpholines; Multivariate Analysis; Odds Ratio; Phenprocoumon; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Sex Factors; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome	2014
Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. The Annals of pharmacotherapy, 2014, Volume: 48, Issue:10 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Hemorrhage; Humans; Inappropriate Prescribing; Male; Middle Aged; Morpholines; Prospective Studies; Pyridines; Rivaroxaban; Thiophenes	2014
Development of delayed cardiac tamponade 55 days after catheter ablation for atrial fibrillation with a new oral anticoagulant. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 41, Issue:2 Topics: Aged; Atrial Fibrillation; Cardiac Tamponade; Catheter Ablation; Echocardiography, Doppler; Follow-Up Studies; Humans; Male; Morpholines; Pericardiocentesis; Pleural Effusion; Postoperative Complications; Rare Diseases; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome	2014
Atrial fibrillation choices. Picking an anti-clotting drug. Mayo Clinic health letter (English ed.), 2014, Volume: 32, Issue:6 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Food-Drug Interactions; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2014
A case of rivaroxaban associated intracranial hemorrhage. The western journal of emergency medicine, 2014, Volume: 15, Issue:4 Topics: Aged, 80 and over; Atrial Fibrillation; Factor Xa Inhibitors; Fatal Outcome; Humans; Intracranial Hemorrhages; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes	2014
Treatment of atrial fibrillation. The Medical letter on drugs and therapeutics, 2014, Jul-07, Volume: 56, Issue:1446 Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin	2014
Isolated hemopericardium associated with rivaroxaban: first case report. Pharmacotherapy, 2014, Volume: 34, Issue:9 Topics: Aged; Atrial Fibrillation; Chest Pain; Factor Xa Inhibitors; Humans; Male; Morpholines; Pericardial Effusion; Rivaroxaban; Thiophenes	2014
Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin. Stroke, 2014, Volume: 45, Issue:9 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2014
Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants. Heart, lung & circulation, 2015, Volume: 24, Issue:1 Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Vitamin K	2015
Anticlotting therapy for atrial fibrillation: should you stay with the devil you know? Preventing stroke with warfarin (Coumadin) can be tricky. New anticlotting drugs can help if you accept certain trade-offs--and take them exactly as directed. Harvard men's health watch, 2014, Volume: 18, Issue:9 Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Female; Fibrinolytic Agents; Humans; Male; Morpholines; Patient Education as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration; Warfarin	2014
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:10 Topics: Administration, Oral; Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Combined Modality Therapy; Dabigatran; Female; Heparin; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Radio Waves; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin	2014
Intravenous thrombolysis in stroke patients receiving rivaroxaban. European journal of neurology, 2014, Volume: 21, Issue:1 Topics: Aged; Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy	2014
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. Journal of medical economics, 2014, Volume: 17, Issue:11 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health Expenditures; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin	2014
[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China]. Zhonghua nei ke za zhi, 2014, Volume: 53, Issue:5 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; China; Comorbidity; Diabetes Mellitus; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Hypertension; Incidence; Inpatients; Male; Morpholines; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2014
Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke. Stroke, 2014, Volume: 45, Issue:10 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin	2014
Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions? Annals of medicine, 2014, Volume: 46, Issue:8 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Early Detection of Cancer; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Incidence; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thiophenes; Warfarin	2014
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation]. Kardiologiia, 2014, Volume: 54, Issue:7 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Models, Statistical; Morpholines; Myocardial Infarction; Prognosis; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Russia; Stroke; Thiophenes; Warfarin	2014
Anticoagulant therapy: Rivaroxaban for patients with AF undergoing cardioversion. Nature reviews. Cardiology, 2014, Volume: 11, Issue:11 Topics: Atrial Fibrillation; Electric Countershock; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Thiophenes; Vitamin K	2014
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2015, Volume: 17, Issue:2 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Denmark; Female; Heart Failure; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Myocardial Ischemia; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Registries; Renal Insufficiency, Chronic; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin	2015
Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies. Hospital practice (1995), 2014, Volume: 42, Issue:3 Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Length of Stay; Male; Middle Aged; Morpholines; Retrospective Studies; Rivaroxaban; Socioeconomic Factors; Stroke; Thiophenes; Warfarin	2014
Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:6 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin	2014
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:6 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Coumarins; Dabigatran; Humans; Markov Chains; Middle Aged; Morpholines; Netherlands; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; United Kingdom	2014
Novel anticoagulants eliminate the need for left atrial appendage exclusion devices. Circulation, 2014, Oct-21, Volume: 130, Issue:17 Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Thiophenes; Unnecessary Procedures; Warfarin	2014
Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention. European heart journal, 2014, Dec-14, Volume: 35, Issue:47 Topics: Anticoagulants; Aortic Valve Insufficiency; Atrial Fibrillation; Female; Humans; Male; Mitral Valve Insufficiency; Morpholines; Thiophenes; Warfarin	2014
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial. BMC family practice, 2014, Oct-25, Volume: 15 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Family Practice; Female; Germany; Guideline Adherence; Heart Diseases; Heart Valve Prosthesis; Humans; International Normalized Ratio; Male; Mass Screening; Middle Aged; Morpholines; Practice Guidelines as Topic; Process Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Thrombosis; Venous Thromboembolism	2014
Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use. DukeMedicine healthnews, 2014, Volume: 20, Issue:9 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2014
Acute thrombocytopenia after initiating anticoagulation with rivaroxaban. Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:21 Topics: Aged; Anticoagulants; Atrial Fibrillation; Humans; Intracranial Hemorrhages; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombocytopenia; Warfarin	2014
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 41, Issue:3 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Cryosurgery; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Morpholines; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2014
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. Canadian family physician Medecin de famille canadien, 2014, Volume: 60, Issue:11 Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Family Practice; Hemorrhage; Humans; Morpholines; Preoperative Care; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Time Factors; Venous Thromboembolism	2014
ACP Journal Club: in nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age. Annals of internal medicine, 2014, Nov-18, Volume: 161, Issue:10 Topics: Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Vitamin K; Warfarin	2014
[Rivaroxaban in non valvular atrial fibrillation: subgroups analysis]. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2014, Volume: 82, Issue:1 Topics: Atrial Fibrillation; Electric Countershock; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes	2014
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding. American heart journal, 2015, Volume: 169, Issue:1 Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin	2015
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. The Annals of pharmacotherapy, 2015, Volume: 49, Issue:3 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2015
Criteria for prescribing dabigatrin extexilate and rivaroxaban really appropriate? Comment. The Annals of pharmacotherapy, 2015, Volume: 49, Issue:1 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Female; Humans; Inappropriate Prescribing; Male; Morpholines; Pyridines; Thiophenes	2015
Criteria for prescribing dabigatrin extexilate and rivaroxaban really appropriate? Authors' reply. The Annals of pharmacotherapy, 2015, Volume: 49, Issue:1 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Female; Humans; Inappropriate Prescribing; Male; Morpholines; Pyridines; Thiophenes	2015
[Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room]. Journal des maladies vasculaires, 2015, Volume: 40, Issue:1 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Emergency Service, Hospital; Female; France; Hemorrhage; History, Ancient; Hospitalization; Humans; Male; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes	2015
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation, 2015, Mar-17, Volume: 131, Issue:11 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Drug Utilization; Female; Hemorrhage; Hospitalization; Humans; Kidney; Kidney Failure, Chronic; Male; Matched-Pair Analysis; Middle Aged; Morpholines; Poisson Distribution; Practice Patterns, Physicians'; Renal Dialysis; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Warfarin	2015
Novel anticoagulants make life easier for patients with atrial fibrillation. The new drugs have many advantages over Coumadin--but they aren't perfect--and they have no antidotes in case of overdose. DukeMedicine healthnews, 2014, Volume: 20, Issue:1 Topics: Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin	2014
Defining non-valvular atrial fibrillation while selecting anticoagulation therapy. British journal of hospital medicine (London, England : 2005), 2015, Volume: 76, Issue:2 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes	2015
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit). The American journal of cardiology, 2015, Mar-01, Volume: 115, Issue:5 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Dabigatran; Hemorrhage; Humans; Male; Medical Audit; Morpholines; Predictive Value of Tests; Primary Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin	2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Lancet (London, England), 2015, Jun-13, Volume: 385, Issue:9985 Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Death, Sudden; Diabetes Mellitus; Digoxin; Factor Xa Inhibitors; Female; Heart Failure; Heart Rate; Humans; Intracranial Embolism; Male; Morpholines; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Rivaroxaban; Sex Distribution; Stroke; Thiophenes; Vitamin K; Warfarin	2015
Rivaroxaban therapy resulting in the resolution of right atrial thrombosis resistant to ordinary control with warfarin in a patient with atrial fibrillation. Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:6 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Coronary Thrombosis; Factor Xa Inhibitors; Heart Atria; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Vitamin K; Warfarin	2015
Successful intravenous thrombolysis following full dose rivaroxaban 5 hours before ictus. British journal of hospital medicine (London, England : 2005), 2015, Volume: 76, Issue:4 Topics: Administration, Oral; Atrial Fibrillation; Brain Ischemia; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Follow-Up Studies; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Middle Aged; Morpholines; Rivaroxaban; Severity of Illness Index; Thiophenes; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator	2015
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation. Circulation, 2015, Apr-21, Volume: 131, Issue:16 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Humans; Kidney Diseases; Kidney Function Tests; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia	2015
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ (Clinical research ed.), 2015, Apr-24, Volume: 350 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Medicaid; Middle Aged; Morpholines; Patient Selection; Practice Patterns, Physicians'; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; United States; Warfarin	2015
Safety of new oral anticoagulants. BMJ (Clinical research ed.), 2015, Apr-24, Volume: 350 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Thiophenes; Warfarin	2015
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ (Clinical research ed.), 2015, Apr-24, Volume: 350 Topics: Administration, Oral; Adult; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Observational Studies as Topic; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; United States; Warfarin	2015
[Periprocedural management of anticoagulation in patients undergoing atrial fibrillation ablation]. Revue medicale suisse, 2015, Mar-04, Volume: 11, Issue:464 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Thromboembolism	2015
Anticoagulation therapy: Bleeding no worse with novel agents. Nature reviews. Cardiology, 2015, Volume: 12, Issue:7 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Thiophenes; Warfarin	2015
[Prevention and emergency measures]. MMW Fortschritte der Medizin, 2015, Apr-16, Volume: 157, Issue:7 Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome	2015
Effective antidotes for new anticoagulants. BMJ (Clinical research ed.), 2015, May-26, Volume: 350 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Thiophenes; Warfarin	2015
Rivaroxaban 10mg/d in severe renal failure does not prevent ischemic events in premorbid neurologic disease. Neurologia i neurochirurgia polska, 2015, Volume: 49, Issue:3 Topics: Aged, 80 and over; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Morpholines; Recurrence; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes	2015
Meta-analysis should not be subject to selectivity and imbalance. BMJ (Clinical research ed.), 2015, Jun-24, Volume: 350 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Thiophenes; Warfarin	2015
[The X-VeRT study]. Giornale italiano di cardiologia (2006), 2015, Volume: 16, Issue:6 Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Electric Countershock; Embolism; Factor Xa Inhibitors; Heart Diseases; Hemorrhage; Humans; International Normalized Ratio; Middle Aged; Morpholines; Multicenter Studies as Topic; Myocardial Infarction; Prospective Studies; Randomized Controlled Trials as Topic; Research Design; Risk; Rivaroxaban; Stroke; Thiophenes; Thrombophilia; Time Factors; Treatment Outcome; Vitamin K; Warfarin	2015
Neither dabigatran nor rivaroxaban were linked to increased GI bleeding compared with warfarin. Annals of internal medicine, 2015, Sep-15, Volume: 163, Issue:6 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Thiophenes; Warfarin	2015
Point-of-Care Warfarin Monitoring in the ROCKET AF Trial. The New England journal of medicine, 2016, Feb-25, Volume: 374, Issue:8 Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Thiophenes; Warfarin	2016
Response to the letter concerning the article "Rivaroxaban in secondary cardiogenic stroke prevention: two-year single-centre experience based on follow-up of 209 patients". Kardiologia polska, 2016, Volume: 74, Issue:5 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Follow-Up Studies; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Treatment Outcome; Warfarin	2016
Point-of-Care Warfarin Monitoring in the ROCKET AF Trial. The New England journal of medicine, 2016, 07-28, Volume: 375, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Thiophenes; Warfarin	2016
Point-of-Care Warfarin Monitoring in the ROCKET AF Trial. The New England journal of medicine, 2016, 07-28, Volume: 375, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Thiophenes; Warfarin	2016
Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban. Journal of clinical pharmacology, 2010, Volume: 50, Issue:9 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Blood Coagulation Disorders; Clinical Trials as Topic; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin	2010
Factor Xa and thrombin as targets for new oral anticoagulants. Thrombosis research, 2011, Volume: 127 Suppl 2 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K	2011
New alternative to warfarin may help reduce stroke risk in patients with AF. JAMA, 2011, Jan-05, Volume: 305, Issue:1 Topics: Aged; Anticoagulants; Atrial Fibrillation; Drug Approval; Humans; Morpholines; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin	2011
What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thrombosis and haemostasis, 2011, Volume: 105, Issue:4 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes	2011
Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs. Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:8 Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biomarkers; Chronic Disease; Creatinine; Dabigatran; Fibrinolytic Agents; Glomerular Filtration Rate; Humans; Incidence; Kidney; Kidney Diseases; Morpholines; Netherlands; Patient Selection; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Severity of Illness Index; Thiophenes	2011
[Current and future therapies for prophylaxis of thromboembolism in atrial fibrillation]. MMW Fortschritte der Medizin, 2011, Apr-14, Volume: 153, Issue:15 Topics: Anticoagulants; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Guideline Adherence; Hemorrhage; Humans; Intracranial Embolism; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K	2011
New options in anticoagulation for atrial fibrillation. The New England journal of medicine, 2011, Sep-08, Volume: 365, Issue:10 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intention to Treat Analysis; Intracranial Hemorrhages; Morpholines; Rivaroxaban; Thiophenes; Warfarin	2011
New anticoagulants: moving on from scientific results to clinical implementation. Annals of medicine, 2011, Volume: 43, Issue:8 Topics: Acute Coronary Syndrome; Anticoagulants; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diet; Drug Interactions; Factor VIIa; Factor Xa Inhibitors; Humans; Kidney; Life Style; Monitoring, Physiologic; Morpholines; Recombinant Proteins; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K	2011
A new era for anticoagulation in atrial fibrillation. The New England journal of medicine, 2011, Sep-15, Volume: 365, Issue:11 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin	2011
Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations. The New England journal of medicine, 2011, Oct-27, Volume: 365, Issue:17 Topics: Advisory Committees; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Approval; Government Regulation; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration	2011
FDA advisory decision highlights some problems inherent in pragmatic trials. JAMA, 2011, Nov-02, Volume: 306, Issue:17 Topics: Advisory Committees; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Approval; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; United States; United States Food and Drug Administration; Warfarin	2011
Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation. Journal of neurology, 2012, Volume: 259, Issue:1 Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K	2012
[Anticoagulation in atrial fibrillation: a new era has begun]. Hamostaseologie, 2012, Volume: 32, Issue:1 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism	2012
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England journal of medicine, 2011, 12-15, Volume: 365, Issue:24 Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Thiophenes; Warfarin	2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England journal of medicine, 2011, 12-15, Volume: 365, Issue:24 Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Thiophenes; Warfarin	2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England journal of medicine, 2011, 12-15, Volume: 365, Issue:24 Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Thiophenes; Warfarin	2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England journal of medicine, 2011, 12-15, Volume: 365, Issue:24 Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Thiophenes; Warfarin	2011
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thrombosis and haemostasis, 2012, Volume: 107, Issue:3 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cohort Studies; Computer Simulation; Dabigatran; Decision Making, Computer-Assisted; Denmark; Humans; Intracranial Hemorrhages; Morpholines; Population Groups; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2012
What's the "go to" anticoagulant for stroke prevention in atrial fibrillation? Thrombosis and haemostasis, 2012, Volume: 107, Issue:3 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes	2012
Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS. Expert review of cardiovascular therapy, 2012, Volume: 10, Issue:3 Topics: Acute Coronary Syndrome; American Heart Association; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Fibrinolytic Agents; Humans; Lactones; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; United States; Venous Thromboembolism	2012
Rivaroxaban and recurrent stroke prevention in AF. The Lancet. Neurology, 2012, Volume: 11, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
[Update on current care guidelines: atrial fibrillation]. Duodecim; laaketieteellinen aikakauskirja, 2012, Volume: 128, Issue:4 Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Finland; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Warfarin	2012
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. Journal of medical economics, 2012, Volume: 15, Issue:4 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Control; Dabigatran; Endpoint Determination; Health Expenditures; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; United States; Warfarin	2012
[Anticoagulant therapeutics: In order not to jeopardize a potential therapeutical progress]. Presse medicale (Paris, France : 1983), 2012, Volume: 41, Issue:6 Pt 1 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes	2012
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. Journal of the American College of Cardiology, 2012, Aug-21, Volume: 60, Issue:8 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome	2012
[Expanded arsenal in atrial fibrillation: bye-bye marcumar?]. MMW Fortschritte der Medizin, 2012, Jan-19, Volume: 154, Issue:1 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Drug Substitution; Factor Xa Inhibitors; Germany; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Thiophenes; Thromboembolism	2012
Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. The American journal of cardiology, 2012, Sep-15, Volume: 110, Issue:6 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Humans; Markov Chains; Medicare; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin	2012
Oral anticoagulants for atrial fibrillation: Which one to choose? Advance for NPs & PAs, 2012, Volume: 3, Issue:5 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Costs; Drug Substitution; Humans; Morpholines; Pyridines; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation. European heart journal, 2012, Volume: 33, Issue:17 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Drug Costs; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes	2012
Indirect comparison studies--are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation. Thrombosis and haemostasis, 2012, Volume: 108, Issue:3 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombophilia	2012
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circulation. Cardiovascular quality and outcomes, 2012, Jul-01, Volume: 5, Issue:4 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin	2012
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. The American journal of medicine, 2012, Volume: 125, Issue:9 Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Risk Assessment; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin	2012
New oral anticoagulant in atrial fibrillation: are they comparable? International angiology : a journal of the International Union of Angiology, 2012, Volume: 31, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes	2012
Is rivaroxaban safer and more effective than warfarin in patients with atrial fibrillation and stroke or TIA? The Lancet. Neurology, 2012, Volume: 11, Issue:8 Topics: Anticoagulants; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Morpholines; Stroke; Thiophenes; Warfarin	2012
[The ROCKET AF study]. Giornale italiano di cardiologia (2006), 2012, Volume: 13, Issue:9 Topics: Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Warfarin	2012
Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what's next? Thrombosis and haemostasis, 2012, Volume: 108, Issue:3 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombophilia	2012
J-ROCKET AF trial increased expectation of lower-dose rivaroxaban made for Japan. Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:9 Topics: Anticoagulants; Atrial Fibrillation; Embolism; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
Danger ahead: watch out for indirect comparisons! Journal of the American College of Cardiology, 2012, Aug-21, Volume: 60, Issue:8 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes	2012
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Thrombosis and haemostasis, 2012, Volume: 108, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Embolism; Humans; Markov Chains; Models, Economic; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2012
Rivaroxaban in atrial fibrillation. Vascular health and risk management, 2012, Volume: 8 Topics: Anticoagulants; Atrial Fibrillation; Humans; International Normalized Ratio; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin	2012
Rivaroxaban and other novel anticoagulants for stroke prevention in atrial fibrillation: time to embrace the future. Heart (British Cardiac Society), 2013, Volume: 99, Issue:6 Topics: Aged; Anticoagulants; Atrial Fibrillation; Female; Forecasting; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes	2013
Catheter ablation of atrial fibrillation: the need for studies to assess the efficacy and safety of novel anticoagulants. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2013, Volume: 36, Issue:1 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Morpholines; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; United States; Warfarin	2013
How big is the impact of the warfarin cost on the cost-effectiveness of rivaroxoban for stroke prevention in atrial fibrillation? The American journal of cardiology, 2012, Nov-01, Volume: 110, Issue:9 Topics: Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Stroke; Thiophenes; Warfarin	2012
Rivaroxaban in acute coronary syndromes and atrial fibrillation: rivaroxaban shown to reduce cardiovascular deaths in STEMI patients. Cardiovascular journal of Africa, 2012, Volume: 23, Issue:9 Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Electrocardiography; Expert Testimony; Humans; Morpholines; Myocardial Infarction; Practice Guidelines as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiophenes; Treatment Outcome	2012
[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes]. Revista clinica espanola, 2012, Volume: 212 Suppl 1 Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin	2012
[Rivaroxaban versus warfarin: results of the ROCKET study]. Ideggyogyaszati szemle, 2012, Sep-30, Volume: 65, Issue:9-10 Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Double-Blind Method; Humans; Morpholines; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Treatment Outcome; Warfarin	2012
Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ (Clinical research ed.), 2012, Nov-05, Volume: 345 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Male; Morpholines; Pharmacovigilance; Primary Prevention; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin	2012
New oral anticoagulants. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2013, Mar-05, Volume: 185, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Canada; Contraindications; Dabigatran; Drug Dosage Calculations; Drug Interactions; Humans; Morpholines; Postoperative Complications; Pyridines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis	2013
[New anticoagulants: better knowledge, better prescriptions]. Revue medicale suisse, 2012, Jan-18, Volume: 8, Issue:324 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K	2012
Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran. Prescrire international, 2012, Volume: 21, Issue:132 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Kidney; Morpholines; Rivaroxaban; Thiophenes; Warfarin	2012
Reply: To PMID 22575324. Journal of the American College of Cardiology, 2013, Feb-05, Volume: 61, Issue:5 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Stroke; Thiophenes	2013
Lack of stroke subtype information may hinder indirect comparison between the ROCKET-AF and other trials of new oral anticoagulants. Journal of the American College of Cardiology, 2013, Feb-05, Volume: 61, Issue:5 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Stroke; Thiophenes	2013
Transitions of care in anticoagulation management for patients with atrial fibrillation. Hospital practice (1995), 2012, Volume: 40, Issue:4 Topics: Administration, Oral; Aftercare; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Continuity of Patient Care; Dabigatran; Drug Monitoring; Drug Substitution; Emergencies; Hemorrhage; Humans; Morpholines; Patient Education as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
"R" for "renal" and for "risk": refining risk stratification for stroke in atrial fibrillation. Circulation, 2013, Jan-15, Volume: 127, Issue:2 Topics: Atrial Fibrillation; Embolism; Factor Xa; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Vitamin K	2013
Reconsideration of anticoagulant therapy in Japanese patients with atrial fibrillation and moderate renal impairment. Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:3 Topics: Anticoagulants; Asian People; Atrial Fibrillation; Female; Humans; Male; Morpholines; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes	2013
Discontinuation of rivaroxaban: filling in the gaps. Journal of the American College of Cardiology, 2013, Feb-12, Volume: 61, Issue:6 Topics: Atrial Fibrillation; Blood Coagulation; Female; Humans; Male; Morpholines; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin	2013
[New anticoagulants]. Hamostaseologie, 2008, Volume: 28, Issue:1-2 Topics: Anticoagulants; Atrial Fibrillation; Education, Medical, Continuing; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Humans; Morpholines; Polysaccharides; Rivaroxaban; Thiophenes; Treatment Outcome	2008